๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial) NCT07073365Phase 21 site๐Ÿ“ Busan Pusan National University Hospital ยท Tests: Local Therapy (Surgery or Radiotherapy) A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation NCT06102928NA1 site๐Ÿ“ Kunming Kunming Medical University ยท Tests: Combined therapy of anlotinib and aumolertinib A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases NCT05033691NA1 site๐Ÿ“ Jerusalem Hadassah Medical Organization ยท Tests: Stereotactic surgery Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer. NCT06238882NA1 site๐Ÿ“ Mexico City Instituto Nacional de Cancerologia de Mexico ยท Tests: Nitroglycerin Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib NCT04486833Phase 1, Phase 210 sites๐Ÿ“ Los Angeles๐Ÿ“ Lone Tree๐Ÿ“ Urbana Genprex, Inc. ยท Tests: quaratusugene ozeplasmid, osimertinib, Platinum-Based Chemotherapy Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis NCT06643000NA2 sites๐Ÿ“ Zhengzhou๐Ÿ“ Zhengzhou Henan Cancer Hospital ยท Tests: furmonertinib An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer. NCT07357597Phase 441 sites๐Ÿ“ Tucson๐Ÿ“ Hot Springs๐Ÿ“ Little Rock AstraZeneca ยท Tests: Dexamethasone mouthwash, Datopotamab Deruxtecan (Dato-DXd) Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge NCT04335292Phase 210 sites๐Ÿ“ Vancouver๐Ÿ“ Vancouver๐Ÿ“ Brampton Mark Vincent ยท Tests: Osimertinib First-Line, Platinum + Pemetrexed Chemotherapy Second-Line, Osimertinib Third-Line Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366Phase 1, Phase 266 sites๐Ÿ“ Phoenix๐Ÿ“ Tucson๐Ÿ“ Los Angeles Genmab ยท Tests: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors NCT07070232Phase 1, Phase 277 sites๐Ÿ“ Phoenix๐Ÿ“ San Francisco๐Ÿ“ Hartford BioNTech SE ยท Tests: BNT326, Pumitamig, Itraconazole, Paroxetine First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) NCT05099172Phase 1, Phase 294 sites๐Ÿ“ Gilbert๐Ÿ“ Duarte๐Ÿ“ Atlanta Bayer ยท Tests: BAY2927088_formulation A, BAY2927088_formulation B_1, BAY2927088_formulation B_2, BAY2927088_formulation B_3 Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations NCT07185997Phase 3139 sites๐Ÿ“ Fullerton๐Ÿ“ Los Angeles๐Ÿ“ Orange ArriVent BioPharma, Inc. ยท Tests: Firmonertinib, EGFR-TKI inhibitor based on investigator's choice A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC NCT06951464Phase 21 site๐Ÿ“ Chengdu Sichuan University ยท Tests: BL-B01D1, Almonertinib A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases NCT06970639Phase 31 site๐Ÿ“ Guangdong Allist Pharmaceuticals, Inc. ยท Tests: Furmonertinib Mesilate Tablets, Carboplatin Injection, Cisplatin for injection, Pemetrexed Disodium for Injection, Osimโ€ฆ Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) NCT07100080Phase 2, Phase 3187 sites๐Ÿ“ Irvine๐Ÿ“ Orange๐Ÿ“ Edwards Bristol-Myers Squibb ยท Tests: Iza-bren, Carboplatin, Cisplatin, Pemetrexed Osimertinib and Cyclosporine A to Enhance Antitumor Efficacy in NSCLC NCT07874490Phase 21 site๐Ÿ“ New York NYU Langone Health ยท Tests: Osimertinib, Cyclosporine A (CsA), ctDNA Biopsy Panel A Phase 1/1b Study of IAM1363 in HER2 Cancers NCT06253871Phase 153 sites๐Ÿ“ La Jolla๐Ÿ“ Los Angeles๐Ÿ“ Aurora Iambic Therapeutics, Inc ยท Tests: IAM1363 To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy NCT04853342Phase 31 site๐Ÿ“ Suzhou Allist Pharmaceuticals, Inc. ยท Tests: Drug: Furmonertinib 80 mg, Furmonertinib 80 mg placebo To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy NCT06192849Phase 21 site๐Ÿ“ Chengdu Juan LI, MD ยท Tests: Furmonertinib A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy NCT07548060Phase 21 site๐Ÿ“ Tianjin Tianjin Medical University Cancer Institute and Hospital ยท Tests: sacituzumab tirumotecan A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer NCT07699328Phase 1, Phase 229 sites๐Ÿ“ Bedford Park๐Ÿ“ Clayton๐Ÿ“ Toronto Voronoi, Inc ยท Tests: VRN110755 A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC NCT07058519Phase 21 site๐Ÿ“ Shanghai Shanghai Chest Hospital ยท Tests: Osimertinib-based adaptive treatment, Osimertinib 80 MG Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer NCT07329322Phase 21 site๐Ÿ“ Beijing Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ยท Tests: Sacituzumab Tirumotecan, Osimertinib JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study NCT07518160Phase 22 sites๐Ÿ“ Shanghai๐Ÿ“ Shanghai Shanghai Junshi Bioscience Co., Ltd. ยท Tests: JS212 for Injection๏ผ‹JS111 capsules (AP-L1898) A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer NCT05498428Phase 2110 sites๐Ÿ“ La Jolla๐Ÿ“ Orange๐Ÿ“ Stanford Janssen Research & Development, LLC ยท Tests: Amivantamab, Lazertinib, Carboplatin, Pemetrexed, Direct Oral Anticoagulant (DOAC) A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations NCT06735391Phase 31 site๐Ÿ“ Guangzhou Shanghai JMT-Bio Inc. ยท Tests: JMT101, Osimertinib A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC NCT07462377Phase 18 sites๐Ÿ“ Los Angeles๐Ÿ“ East Brunswick๐Ÿ“ Lake Success EpiBiologics ยท Tests: EPI-326 A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) NCT06452277Phase 3279 sites๐Ÿ“ Newport Beach๐Ÿ“ San Diego๐Ÿ“ San Francisco Bayer ยท Tests: Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients NCT06071013Phase 1, Phase 21 site๐Ÿ“ Taichung China Medical University Hospital ยท Tests: Nintedanib, gefitinib, erlotinib, afatinib, osimertinib APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors NCT03175224Phase 235 sites๐Ÿ“ Los Angeles๐Ÿ“ Tampa๐Ÿ“ Boston Apollomics Inc. ยท Tests: APL-101 Oral Capsules
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy